Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-myeloablative Haploidentical HCT for Sickle Cell Disease
NCT06145282Phase 2Active, not recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Dec 2023
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of briquilimab in sickle cell disease (SCD), sponsored by National Heart, Lung, and Blood Institute. Started Dec 2023; status: active, not recruiting.
02
Drugs
briquilimab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT06145282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06145282.